Go to Page # Page of 13

Safety Evaluation of 2

 Maja Janas PhD
Description: This presentation provides information about the Safety Evaluation's Important factors include the ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of product candidates.
Views: 3165
Domain: Medical
Category: Biotech/Pharma
Safety Evaluation of 2'-Deoxy-2'-Fluoro-Modified
Nucleotides in GalNAc-siRNA Conjugates
Maja Janas, PhD, DABT
Principal Scientist, Early Development
14th Annual Meeting of the OTS
October 3rd, 2018


© 2018 Alnylam Pharmaceuticals, Inc.

Alnylam Forward Looking Statements
This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities ... See more

Recent Presentations

Philippe Ravaud
21 May, 2019
Ron Emerson,
20 May, 2019
Lyndsey Scull
19 May, 2019